PFBT
KROS icon

Parkside Financial Bank & Trust’s Keros Therapeutics KROS Stock Holding History

Parkside Financial Bank & Trust’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$588 Hold
55
– – ﹤0.01% 2568
2026
Q1 		$608 Hold
55
– – ﹤0.01% 2514
2025
Q4 		$1.12K Hold
55
– – ﹤0.01% 2308
2025
Q3 		$871 Hold
55
– – ﹤0.01% 2341
2025
Q2 		$735 Hold
55
– – ﹤0.01% 2364
2025
Q1 		$558 Buy
+55
New +$639 ﹤0.01% 2317

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Parkside Financial Bank & Trust's KROS Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Keros Therapeutics (KROS) position steady in Q2 2026 at 55 shares worth $588. The position accounts for ﹤0.01% of the portfolio, ranked #2568.

Parkside Financial Bank & Trust first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.12K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Parkside Financial Bank & Trust held 55 shares of Keros Therapeutics worth $588 as of Q2 2026.
  • Parkside Financial Bank & Trust left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2568 holding.
  • Parkside Financial Bank & Trust first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Parkside Financial Bank & Trust's Keros Therapeutics position peaked at $1.12K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.